Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands; Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Universidad San Francisco de Quito, Hospital Eugenio Espejo, Quito, Ecuador.
Ann Hepatol. 2019 Nov-Dec;18(6):786-787. doi: 10.1016/j.aohep.2019.07.009. Epub 2019 Aug 26.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Interestingly, the great majority of individuals affected by the tumor have underlying liver disease, therefore narrowing the population to be screened. Still, however, there is a clear lack of blood biomarkers, and surveillance in those at risk is performed by frequent imaging of the liver. A variety of multinational collaborations are currently invested in finding biomarkers for HCC based on liver-produced proteins. A new approach with assessment of peripheral proteins might be necessary for the successful early detection of this malignancy.
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。有趣的是,绝大多数患有肿瘤的个体都有潜在的肝脏疾病,因此筛选的人群范围变窄。然而,目前仍然缺乏血液生物标志物,对于高危人群,通过频繁的肝脏成像进行监测。目前,许多跨国合作正在致力于寻找基于肝脏产生的蛋白质的 HCC 生物标志物。对于这种恶性肿瘤的成功早期检测,评估外周蛋白可能是一种必要的新方法。